Filing Details

Accession Number:
0000950170-24-136785
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-16 17:59:32
Reporting Period:
2024-12-12
Accepted Time:
2024-12-16 17:59:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1160308 Savara Inc SVRA Pharmaceutical Preparations (2834) 841318182
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1408498 L David Lowrance 1717 Langhorne Newtown Road
Suite 300
Langhorne PA 19047
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-12-12 100,000 $0.00 442,355 No 4 A Direct
Common Stock Disposition 2024-12-13 12,000 $0.00 430,355 No 4 G Direct
Common Stock Disposition 2024-12-13 24,350 $3.21 406,005 No 4 F Direct
Common Stock Disposition 2024-12-16 25,000 $3.33 381,005 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 G Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2024-12-12 300,000 $0.00 300,000 $3.35
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
300,000 2034-12-12 No 4 A Direct
Footnotes
  1. Represents restricted stock units ("RSUs") that vest in full on December 12, 2026, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
  2. The reporting person made a bona fide gift to The McCallie School. The reporting person does not have voting or investment power with respect to the shares held by The McCallie School.
  3. Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units.
  4. Represents shares sold to satisfy tax liability upon the vesting of restricted stock units.
  5. The price is a weighted average sales price. The sale prices ranged from $3.29 to $3.36. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  6. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 12, 2024, subject to the reporting person's continued service with the Issuer.